Malvern Instruments Launches its New OMNISEC GPC/SEC
A completely new gel permeation/size exclusion chromatography (GPC/SEC) platform from Malvern Instruments breaks new ground in delivering the high performance, ease of use and productivity demanded in today’s analytical laboratories. Malvern’s innovative OMNISEC platform integrates highly efficient sample separation via the OMNISEC RESOLVE module and high sensitivity analysis using OMNISEC REVEAL, a fully integrated multi-detector array. The system has applications wherever there is a need for detailed analysis and understanding of natural or synthetic polymers, proteins and macromolecules.
GPC/SEC is a two-step analytical process that involves separating a sample on the basis of its size and then analyzing the resulting fractions. The technique delivers molecular weight, molecular size and structural information, all of which define the performance of many industrially important materials. Coupling the efficient sample separation of OMNISEC RESOLVE with the fully optimized, multi-detector, information-rich analysis delivered by OMNISEC REVEAL, Malvern has produced a market-leading solution for researchers and formulators developing novel natural and synthetic polymers, pharmaceutical and biopharmaceutical products and foods.
OMNISEC REVEAL includes the following four detectors: refractive index (RI), UV/Vis Photodiode array (UV-PDA), low angle/right angle light scattering (RALS/LALS) and viscometer. Its light scattering detector is the most sensitive on the market meaning it can accurately measure molecular weights as low as 200 Da or injection masses of 100 ng. A new self-balancing viscometer design with a user exchangeable capillary bridge boosts instrument productivity and cuts lifetime costs by extending viscometer life, reducing instrument downtime and minimizing maintenance requirements. Excellent temperature control across the complete module, including the integrated detectors and inter-detector tubing, further boosts the accuracy of all measurements.
OMNISEC RESOLVE consists of a sample degasser, pump, autosampler and column oven, each optimized for precise, high resolution separations. This translates into smooth stable baselines for detector analysis, which in turn boost the accuracy of all measurements. Key features here include a low volume, high efficiency degasser design that enables rapid switchover from one sample type to another, thereby delivering substantial timesaving in busy multi-user labs. The new temperature controlled autosampler eliminates injection waste, minimizing the sample required for routine measurement, and in combination with the column oven maintains all samples under closely controlled conditions throughout the analysis. This is especially important when dealing with materials such as proteins which can be temperature sensitive.
As well as the complete OMNISEC system, OMNISEC REVEAL can be purchased as an individual detector module to add to an existing GPC/SEC system. However, there are substantial advantages to an integrated system, with benefits including: smaller inter-detector volumes, reduced band broadening and better temperature control. These deliver improved sample stability and enhanced accuracy, and the day-to-day productivity efficiencies that stem from using a system that has been fully and optimally integrated to meet modern GPC/SEC requirements.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance